Swarthmore Group Inc. maintained its stake in shares of Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,725 shares of the company’s stock at the end of the third quarter. Swarthmore Group Inc.’s holdings in Johnson & Johnson were worth $2,685,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in JNJ. Americafirst Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $101,000. Tuttle Tactical Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $103,000. Lenox Wealth Management Inc. increased its stake in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. increased its stake in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. purchased a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $127,000. 64.13% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) traded down 0.57% during midday trading on Tuesday, hitting $112.48. 7,799,259 shares of the stock traded hands. The company’s 50 day moving average price is $115.97 and its 200 day moving average price is $118.40. Johnson & Johnson has a 12 month low of $94.28 and a 12 month high of $126.07. The firm has a market cap of $306.01 billion, a PE ratio of 19.74 and a beta of 0.75.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The business had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. During the same quarter in the previous year, the firm earned $1.49 earnings per share. The company’s revenue was up 4.2% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post $6.72 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be paid a dividend of $0.80 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date is Friday, November 18th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.84%. Johnson & Johnson’s payout ratio is presently 56.64%.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Financial Market News and is owned by of Financial Market News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international copyright & trademark legislation. The legal version of this story can be viewed at http://www.financial-market-news.com/swarthmore-group-inc-continues-to-hold-stake-in-johnson-johnson-jnj/1209246/.

Several brokerages recently commented on JNJ. Credit Suisse Group AG reissued a “neutral” rating and set a $123.00 price objective on shares of Johnson & Johnson in a research report on Monday, September 19th. Vetr downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $119.60 price target on the stock. in a report on Tuesday, November 1st. Bank of America Corp. reaffirmed a “hold” rating and set a $126.00 price target on shares of Johnson & Johnson in a report on Monday. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price target on the stock in a report on Friday, August 5th. Finally, Jefferies Group raised their price target on shares of Johnson & Johnson from $113.00 to $119.00 and gave the company a “hold” rating in a report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $121.02.

In other Johnson & Johnson news, Director Charles Prince purchased 875 shares of the company’s stock in a transaction dated Friday, October 21st. The shares were acquired at an average price of $114.11 per share, for a total transaction of $99,846.25. Following the completion of the purchase, the director now owns 26,520 shares of the company’s stock, valued at $3,026,197.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.11% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.